Search International and National Patent Collections

1. (WO2018200855) NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING

Pub. No.:    WO/2018/200855    International Application No.:    PCT/US2018/029626
Publication Date: Fri Nov 02 00:59:59 CET 2018 International Filing Date: Fri Apr 27 01:59:59 CEST 2018
IPC: C07D 487/04
C07D 487/08
C07D 471/10
C07D 471/04
C07D 487/00
C07D 487/10
C07D 495/04
C07D 491/056
C07D 519/00
A61K 31/519
A61K 31/4375
A61K 31/438
A61K 31/439
A61K 31/4365
A61K 31/4355
A61P 19/08
A61P 19/02
A61P 35/00
A61P 35/04
A61P 37/00
A61P 43/00
Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors: YU, Paul, B.
HUANG, Wenwei
SANDERSON, Philip, Edward
JIANG, Jian-kang
SHAMIM, Khalida
ZHENG, Wei
HUANG, Xiuli
TAWA, Gregory
LEE, Arthur
ALIMARDANOV, Asaf
HUANG, Junfeng
Title: NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING
Abstract:
The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjogren's syndrome, or diffuse intrinsic pontine glioma (DIPG).